Annual report
9341.TEDINET S100TR24
Period2023-04-01 → 2024-03-31
Filed2024-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥6.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥1.7bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥804m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.7bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥686m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥629m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥8.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥2.8bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.2bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.5bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥777m | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.9bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥624m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥94m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥113m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥179m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥68m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥377m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥60m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥75m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥97.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥76.61 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.96 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.88 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥96.5 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.07 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥324.82 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥229.47 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥91.9 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥48.67 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 70.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 35.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 45.6% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 60.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 138.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 352 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 294 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 242 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 185 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥8.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥6.4bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥4.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥774m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥62m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥666m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥605m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥87m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.7bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥857m | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥2.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.0bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.4bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥738m | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥133m | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.9bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.8bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥96 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.52 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.72 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.35 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥11,085.03 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥95.16 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥72.03 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥320.1 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥225.51 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥88.65 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥46.76 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥16,824.21 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 15.5% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 35.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 46.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 61.4% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 139.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 98.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,794,100 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,598,100 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 80,900 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 7,890 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 7,890 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 322 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 269 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 215 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 159 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 145 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 76
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 44 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥585m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥585m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥150m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥173m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥12m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥16m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥6.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.5bn |
| Medical Platform Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥31m |
| Medical Platform Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥33m |
| Medical Platform Businessreportable segment | employees | at 2024-03-31 | 204 pure |
| Medical Platform Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Medical Platform Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Medical Platform Businessreportable segment | segment assets | at 2024-03-31 | ¥1.0bn |
| Medical Platform Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| Smart Clinic Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥22m |
| Smart Clinic Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥21m |
| Smart Clinic Businessreportable segment | employees | at 2024-03-31 | 55 pure |
| Smart Clinic Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Smart Clinic Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Smart Clinic Businessreportable segment | segment assets | at 2024-03-31 | ¥741m |
| Smart Clinic Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥680m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥53m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥55m |
| —segment total | employees | at 2024-03-31 | 259 pure |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.1bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.1bn |
| —segment total | segment assets | at 2024-03-31 | ¥1.8bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥56m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥58m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥12m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥532m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥532m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥131m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥160m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥13m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥16m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥4.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Medical Platform Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥48m |
| Medical Platform Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥24m |
| Medical Platform Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥4.1bn |
| Medical Platform Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥4.1bn |
| Medical Platform Businessreportable segment | segment assets | at 2023-03-31 | ¥828m |
| Medical Platform Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Smart Clinic Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥27m |
| Smart Clinic Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥11m |
| Smart Clinic Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.9bn |
| Smart Clinic Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.9bn |
| Smart Clinic Businessreportable segment | segment assets | at 2023-03-31 | ¥426m |
| Smart Clinic Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥416m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥75m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥34m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥6.0bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥6.0bn |
| —segment total | segment assets | at 2023-03-31 | ¥1.3bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥88m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥39m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥6.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥6.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 22 pure |
| Medical Platform Businessreportable segment | employees | at 2024-03-31 | 199 pure |
| Smart Clinic Businessreportable segment | employees | at 2024-03-31 | 52 pure |
| —segment total | employees | at 2024-03-31 | 251 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,317
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_ReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 44 | |
| Average number of temporary workers | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 49 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 26 | |
| Number of employees | CurrentYearInstant | 352 | |
| Average number of temporary workers | CurrentYearInstant | 26 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 322 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 25 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 28.9 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 3.5 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5679000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E38215-000MedicalPlatformBusinessReportableSegmentsMember | 199 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E38215-000MedicalPlatformBusinessReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E38215-000SmartClinicBusinessReportableSegmentsMember | 52 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E38215-000SmartClinicBusinessReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember | 251 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 22 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 49 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 25 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 322 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 25 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.067 | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.694 | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.839 | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.671 | |
| Research and development expenses research and development activities | CurrentYearDuration | 46865000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 67569000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 17794100 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 17796100 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 17794100 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 17796100 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 6 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 23 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 53 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 31 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 13 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 3178 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 3304 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 11375 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 5018 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 26026 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 11119 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 73 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 124294 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |